1. CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

3. Introduction/Overview

4. Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

5. Controlling Glycemia Reduces Microvascular Complications: DCCT

6. Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)

7. Underlying Clinical Factors Influencing Incidence of Hypoglycemia in Patients With T2DM

8. CV Safety Trials for the Gliptins: What Was the Point?

9. EMPA-REG OUTCOME and LEADER: Paradigm Shift in T2DM Treatment

10. DPP-4 Inhibitors -- Topline Clinical Trial Results

11. Comparison of MET + SU vs MET + DPP-4i: All-Cause Mortality

12. EMPA-REG: Results for CV Death

13. EMPA-REG OUTCOME and Stroke

14. CANVAS: 2-Fold Increase in Risk of Amputation, Canagliflozin vs Placebo

15. Liraglutide Is a Once-Daily, Human GLP-1 Analogue

16. LEADER: Primary Outcome Results*

17. LEADER: Results for CV Death

18. Other Improvements Observed With Liraglutide in LEADER

19. SUSTAIN-6 (Semaglutide): Primary Outcome Results

20. New Paradigm for Treating the Patient With Both T2DM and CVD

21. How Big a Problem Is Needle Phobia?

22. Side Effects Associated With Liraglutide

23. Is There an Impact on Retinopathy With GLP-1 RAs?

24. Incidence of Pancreatitis in LEADER

25. Potential Mechanisms for CV Benefit Associated With Empagliflozin

26. Changes in Global Longitudinal Strain at 6 Months, Liraglutide vs Metformin

27. Pharmacologic Therapy for T2DM: ADA 2018 Recommendations

28. Clear-Cut Clinical Roles for Liraglutide and Empagliflozin

29. Summary and Conclusions

30. Abbreivations

31. Abbreviations (cont)